Clinical Characteristics and Risk Factors for Severe Immune-Related Liver Injury Following Nivolumab and Ipilimumab Combination Therapy
- DOI
- 10.3390/antib15050079
- Published
- 2026-09-01
- Container
- Antibodies
- Publisher
- MDPI AG
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3390/antib15050079,
title = {Clinical Characteristics and Risk Factors for Severe Immune-Related Liver Injury Following Nivolumab and Ipilimumab Combination Therapy},
author = {Yuichi Yamazaki and Satoru Kakizaki and Yuki Tamura and Yumeo Tateyama and Tatsuma Murakami and Takuya Adachi and Hiroki Tojima and Toshio Uraoka},
year = {2026},
journal = {Antibodies},
doi = {10.3390/antib15050079},
url = {https://doi.org/10.3390/antib15050079}
}RIS
TY - JOUR TI - Clinical Characteristics and Risk Factors for Severe Immune-Related Liver Injury Following Nivolumab and Ipilimumab Combination Therapy AU - Yuichi Yamazaki AU - Satoru Kakizaki AU - Yuki Tamura AU - Yumeo Tateyama AU - Tatsuma Murakami AU - Takuya Adachi AU - Hiroki Tojima AU - Toshio Uraoka PY - 2026 JO - Antibodies DO - 10.3390/antib15050079 UR - https://doi.org/10.3390/antib15050079 ER -
APA
Yamazaki, Y., Kakizaki, S., Tamura, Y., Tateyama, Y., Murakami, T., Adachi, T., Tojima, H., & Uraoka, T. (2026). Clinical Characteristics and Risk Factors for Severe Immune-Related Liver Injury Following Nivolumab and Ipilimumab Combination Therapy. Antibodies. https://doi.org/10.3390/antib15050079
Source records
- crossref · retrieved 2026-09-24T22:16:52.007Z